GlobeNewswire

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
19/03/2026
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy Designation by the FDA [...]
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
19/03/2026
SAN DIEGO and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) today announced that Institutional Shareholder Services (“ISS”), a leading [...]
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
19/03/2026
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies [...]
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
19/03/2026
Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercialization HOUSTON, March 19, 2026 [...]
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
19/03/2026
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in [...]
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
19/03/2026
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readiness for izicopan in [...]
Cylinder Health appoints Terry Boch as CEO as demand grows for digestive health solutions
19/03/2026
Health care technology executive brings more than three decades of leadership experience and a personal connection to digestive health. CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cylinder Health today announced the [...]
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
Conference call will be held today, Thursday, March 19 at 9:00 am ET CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
19/03/2026
WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a [...]
Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
19/03/2026
End-to-end RNA optimization: Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve expression and half-life, delivering top [...]
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
19/03/2026
Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumor activity and reversal of resistance with PLK1 inhibition SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cardiff [...]
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
19/03/2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain [...]
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label study Continued alignment with FDA to consider [...]
Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year period Fourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year period Adjusted EBITDA for Q4 2025 was $85 [...]
Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia
19/03/2026
NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), today announced its [...]
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
19/03/2026
Results illustrate how NetraMark’s advanced AI can potentially support precision enrichment strategies in future trials TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark [...]
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
19/03/2026
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with MYB-Driven Solid Tumor [...]
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
19/03/2026
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PD TM 2026 Initial data indicates significantly higher tracer uptake in patients with genetically [...]
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum